Loading...

The current price of CANF is 0.265 USD — it has decreased -6.36 % in the last trading day.
Can Fite Biopharma Ltd is an Israel-based clinical-stage biopharmaceutical company engaged in developing orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The Company co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. Its technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.
Wall Street analysts forecast CANF stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CANF is 2.50 USD with a low forecast of 2.50 USD and a high forecast of 2.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Can Fite Biopharma Ltd revenue for the last quarter amounts to 155.00K USD, decreased -21.32 % YoY.
Can Fite Biopharma Ltd. EPS for the last quarter amounts to -0.00 USD, decreased % YoY.
Can Fite Biopharma Ltd (CANF) has 5 emplpoyees as of December 16 2025.
Today CANF has the market capitalization of 4.52M USD.